RNA Interference (RNAi) Drug Delivery Market: Industry Overview, Growth, Trends, Opportunities and Forecast Till 2027
According to IMARC Group’s latest report, titled “RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global market reached a value of US$ 54.74 Billion in 2021. RNA interference (RNAi) drug delivery is a fundamental cellular mechanism that studies gene functions in eukaryotic organisms. It is also essential for silencing gene expressions for the development of new drugs. RNAi is considered a potential approach for treating various pathologic conditions, including cardiovascular diseases (CVDs), viral infections and cancer. It includes nonviral delivery of siRNA and viral delivery of shRNA that is used across various preclinical models and molecular targets for its transformational effect on modern medicine.
Request for
a PDF sample of this report: https://www.imarcgroup.com/rna-interference-drug-delivery-market
The global RNA
interference (RNAi) drug delivery market is primarily driven by the increasing
number of academic research institutes performing RNA therapeutic studies. The
rising prevalence of chronic diseases, such as cardiac defects and cancer, is
also propelling the growth of the market. In recent years, the demand for RNAi
has escalated due to its high level of specificity, minor side effects, and
ease of synthesis. Besides this, siRNA or microRNAs (miRNA) helps in developing
personalized medicines and identifying altered cellular molecules and
metabolites. Furthermore, advancements in the field of nanotechnology that
facilitate nanoparticle drug delivery and the overall improvements in the
healthcare infrastructure are expected to provide a positive impact on the
market. Looking forward, IMARC Group expects the global RNA interference (RNAi)
drug delivery market to reach US$ 184.98 Billion by 2027, exhibiting at a CAGR
of 22.5% during 2022-2027.
Checkout
Now: https://www.imarcgroup.com/checkout?id=2758&method=1
As the novel
coronavirus (COVID-19)
crisis takes over the world, we are continuously tracking the changes in the
markets, as well as the industry behaviors of the consumers globally and our
estimates about the latest market trends and forecasts are being done after
considering the impact of this pandemic.
Competitive
Landscape with Key Players:
- Alnylam
     Pharmaceuticals Inc.
- Arrowhead
     Pharmaceuticals Inc.
- CureVac
     AG
- Dicerna
     Pharmaceuticals Inc.
- Gradalis
     Inc.
- Ionis
     Pharmaceuticals Inc
- Merck
     & Co. Inc.
- Moderna
     Inc.
- Quark
     Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Silence
     Therapeutics Plc
- Sirnaomics
     Inc.
Market Segmentation:
Breakup by
Application:
- Infectious
     Disease
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Urology
- Metabolic
     Disorders
- Others
Breakup by
Technology:
- Nanoparticle
     Drug Delivery
- Pulmonary
     Drug Delivery
- Nucleic
     Acid Drug Delivery
- Aptamer
     Drug Delivery
Breakup by Region:
- North
     America (United States, Canada)
- Europe
     (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia
     Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin
     America (Brazil, Mexico, Others)
- Middle
     East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst
for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/rna-interference-drug-delivery-market
Note: We are updating our reports,
If you want the report with the latest primary and secondary data (2022-2027)
including industry trends, market size and Competitive landscape, etc. Click
request free sample report, published report will be delivered to you in PDF
format via email within 24 to 48 hours.
Key
highlights of the
report:                                                    
- Market
     Performance (2016-2021)
- Market
     Outlook (2022-2027)
- Market
     Trends
- Market
     Drivers and Success Factors
- Impact
     of COVID-19
- Value
     Chain Analysis
- Comprehensive
     mapping of the competitive landscape
If you need specific
information that is not currently within the scope of the report, we will
provide it to you as a part of the customization.
Related Reports
by IMARC Group:
Multiple Sclerosis
Therapies Market: https://www.imarcgroup.com/multiple-sclerosis-therapies-market
Portable Medical
Ventilators Market: https://www.imarcgroup.com/portable-medical-ventilators-market
Nucleic Acid
Labelling Market: https://www.imarcgroup.com/nucleic-acid-labelling-market
Latin America
Generic Drug Market: https://www.imarcgroup.com/latin-america-generic-drug-market
North Africa Generic
Drug Market: https://www.imarcgroup.com/north-africa-generic-drug-market
West Africa Generic
Drug Market: https://www.imarcgroup.com/west-africa-generic-drug-market
East Africa Generic
Drug Market: https://www.imarcgroup.com/east-africa-generic-drug-market
Europe Generic Drug
Market: https://www.imarcgroup.com/europe-generic-drug-market
India Minimally
Invasive Surgery Market: https://www.imarcgroup.com/india-minimally-invasive-surgery-market
United States
Minimally Invasive Surgery Market: https://www.imarcgroup.com/united-states-minimally-invasive-surgery-market
About Us:
IMARC Group is a
leading market research company that offers management strategy and market
research worldwide. We partner with clients in all sectors and regions to
identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information
products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high
technology organizations. Market forecasts and industry analysis for
biotechnology, advanced materials, pharmaceuticals, food and beverage, travel
and tourism, nanotechnology and novel processing methods are at the top of the
company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801
USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120
433 0800
Americas: - +1 631
791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800,
+91-120-433-0800

 
 
 
Comments
Post a Comment